

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Cancelled)

3. (Currently Amended) ~~Compounds of general formula (I)~~ A compound according to claim 6, + in which

A or B in each case independently of one another represent hydrogen, tetrazolyl or the group -N(CH₃)₂, -NH-(CO)-pyrrolidinyl, -NH-(CO)-pentyl, -NH-(CO)-hexyl, -NH-(CO)-hexyl-NH₂, -NH-(CO)-C₃H₇, -NH-(CO)-CH₂-phenyl, -NH-(CO)-CH₂-NH₂, -NH-(CO)-C₂H₄-NH₂, -NH-(CO)-CH(NH₂)-CH₃, -NH-(CO)-CH(NH₂)-hydroxyphenyl, -NH-(CO)-CH(NH₂)-CH₂-phenyl, -NH-(CO)-CH(NH₂)-CH₂-hydroxyphenyl, -NH-(CO)-CH(NH-(CO)-CH₃)-CH₂-phenyl, -NH-(CO)-CH₂-NH-(CO)-CH₃, -NH-(CO)-N(C₂H₅)(C₂H₄-piperidinyl), -NH-(CO)-N(CH₃)(C₂H₄-piperidinyl), -NH-(CO)-CH₂-NH(CH₃), -CH₂-N(CH₃)₂, -NH-(CO)NH-CH₂-COOH, hydantoinyl, -CH₂-COOH

~~whereby the~~ wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH₂, -N(CH₃)₂ or -NH-(CO)-CH₃,

and ~~whereby~~ wherein hydantoinyl can be substituted with -CH₃, -CH₂-COOH, or - (CO)-thiazolidinonyl,


X represents or the group -NH-,

R¹ represents halogen and

R² represents hydrogen or the group -NH-(CO)-phenyl

or -C₂H₄-, -C₃H₆- both can optionally be substituted in one or more places, the same way or differently, with cyano, hydroxy, phenyl, naphthyl, imidazolyl, thiazolyl, pyridyl, 2-oxazoliny, piperidinyl, -NH₂, -NH-CH₂-thienyl, -NH-pyridinyl-NO₂, -NH-thiazolyl, -SO₂-thienyl, -SO₂-NH₂, -SO₂-CH₃, -SO₂-C₃H₇, pyrrolidinonyl substituted with -COOH, -NH-(CO)-NH-thienyl, -NH-(CO)-NH-phenyl, -NH-(CO)-NH-C₂H₅, -NH-(CO)-C(CH₃)₃, -NH-(CO)-S-C₂H₅, -NH-(CS)-

NH-C₂H₅, -NH-(CO)-C₂H₅, -NH-(CO)-thienyl, -(CO)-NH-NH₂, -(CO)-NH-CH₂-(CO)-NH₂, -(CO)-NH-C₂H₅, -COOH, whereby the wherein phenyl or the imidazolyl, thiazolyl can optionally be substituted in one or more places, the same way or differently, with hydroxy, -CH₃, -NH-(CO)-CH₂-NH₂, -COOC₂H₅, -COOC(CH₃)₃,




or a diastereomer, enantiomer as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts salt thereof.

A or B in each case independently of one another represent hydrogen or the group -NH-(CO)-pyrrolidinyl, -NH-(CO)-piperidinyl, -NH-(CO)-morpholinyl, -NH-(CO)-hexyl-NH₂, -NH-(CO)-CH(NH₂)-hydroxyphenyl, -NH-(CO)-CH(NH₂)-CH₂-hydroxyphenyl, hydantoin optionally substituted with -CH₃,

R¹ represents halogen and

*NC(=O)C(C)(C)C(=O)N, *NC(=O)C1CC1C(=O)N
*NC(=O)C2CCC2C(=O)N, *NC(=O)C1C(F)(F)F1C(=O)N
*NC(=O)C2CC(=O)NC2=O, *NC(=O)C1CCCC1C(=O)N
*NC(=O)C1CCC2C1C(=O)NC2=O, *NC(=O)C1CCNC1=O
*NC(=O)C1CCSC1=O or



or a diastereomer, enantiomer as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts salt thereof.

5. (Currently Amended) ~~Compounds of general formula (I)~~ A compound according to claim 4, which is

N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[4-[[3-[(1-aminocyclopentyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

N-[3-[[4-[[3-[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

N¹-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopentanedicarboxamide,

(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,

(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,

3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,


3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,

N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-ethyl-N-

[2-(1-piperidinyl)ethyl]-urea,
 N-[3-[[5-bromo-4-[[3-[(2,2-dimethyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[(2S)-2-amino-2-phenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N¹-[3-[[5-bromo-2-[[3-[(2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopropanedicarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-(3-((5-bromo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N1-(3-((5-bromo-2-((3-((1-pyrrolidinylcarbonyl)amino)phenyl)amino)-4-pyrimidinyl)-amino)propyl)-1,1-cyclopropanedicarboxamide,
 N-(3-((5-bromo-4-((3-((1-oxopropyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-(3-((5-iodo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-

pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-4-[[3-[[[(2S)-4-oxo-2-azetidyl]carbonyl]amino]propyl]amino]-2-
pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-
pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or
N-[3-[[4-[[3-[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-
pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
or a pharmaceutically acceptable salt thereof.


6. (Currently Amended) ~~Compounds of general formula (I) according to claim 1, A~~
compound of formula (I)



in which

A or B	in each case independently of one another represent hydrogen or the group $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NR}^3\text{R}^4$, $-\text{N}(\text{C}_{1-6}\text{-hydroxyalkyl})_2$, $-\text{NH}(\text{CO})-\text{R}^5$, $-\text{NHCOOR}^6$, $-\text{NR}^7-(\text{CO})-\text{NR}^8\text{R}^9$, $-\text{NR}^7-(\text{CS})-\text{NR}^8\text{R}^9$, $-\text{COOR}^5$, $-\text{CO}-\text{NR}^8\text{R}^9$, $-\text{SO}_2-\text{CH}_3$, 4-bromo-1-methyl-1 <i>H</i> -pyrazolo-3-yl or C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group $-\text{NH}_2$, $-\text{NH}(\text{CO})-\text{R}^5$, $-\text{SO}_2-\text{NHR}^3$, $-\text{COOR}^5$, $-\text{CONR}^8\text{R}^9$, $-\text{O}(\text{CO})-\text{R}^5$, $-\text{O}(\text{CO})-\text{C}_{1-6}\text{-alkyl}-\text{R}^5$,
X	represents an oxygen atom or the group $-\text{NH}-$,
R^1	represents hydrogen, halogen, hydroxymethyl or the group $-\text{COOH}$, $-\text{COO-iso-propyl}$, $-\text{NO}_2$, $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{COOH}$ or $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{COO}-\text{C}_{1-6}\text{-alkyl}$,

R^2 represents C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group $-NH_2$, $-NH-(CO)O-CH_2$ -phenyl, $-NH-(CO)H$, $-NH-(CO)$ -phenyl, $-NH-(CO)-CH_2-O$ -phenyl, $-NH-(CO)-CH_2$ -phenyl, $-NH-(CO)-CH(NH_2)CH_2$ -phenyl, $-NH-(CO)-CH_2-CH(CH_3)$ -phenyl, $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOH$,



~~whereby the~~ wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C_{1-6} -alkyl or $-(CO)-C(CH_2)-C_2H_5$, or represents C_3 -alkynyl,

R^3 or R^4 in each case independently of one another represent hydrogen or C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, phenyl or hydroxyphenyl,
or

R^3 and R^4 together form a C_{3-6} -heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be ~~interrupted~~ interrupted by one or more $-(CO)-$ groups in the ring and/or optionally can contain one or more possible double bonds in the ring, ~~whereby~~ wherein the C_{3-6} -heterocycloalkylring can optionally be substituted with C_{1-6} -alkyl, C_{1-6} -alkyl- $COOH$ or C_{1-6} -alkyl- NH_2 ,

R^5 represents C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{3-6} -cycloalkyl or phenyl each can optionally

be substituted in one or more places, the same way or differently, with halogen, hydroxy, phenyl or with the group -NH_2 , $\text{-NH(CO)-O-C}_{1-6}\text{-alkyl}$, whereby wherein phenyl itself can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy or $\text{C}_{1-6}\text{-alkyl}$,

R^6 represents $\text{C}_{1-6}\text{-alkyl}$, $\text{C}_{2-6}\text{-alkenyl}$ or phenyl,

R^7 represents hydrogen or $\text{C}_{1-6}\text{-alkyl}$ and

R^8 or R^9 in each case independently of one another represent hydrogen, $\text{C}_{1-6}\text{-alkyl}$, $\text{C}_{2-6}\text{-alkenyl}$, $\text{C}_{3-6}\text{-cycloalkyl}$, aryl or phenyl, whereby wherein aryl or phenyl can optionally be substituted in one or more places, the same way or differently, with hydroxy or the group -NO_2 or $\text{-N(C}_{1-6}\text{-alkyl)}_2$ or

R^8 and R^9 together form a $\text{C}_{3-6}\text{-heterocycloalkylring}$ containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more -(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, whereby wherein the $\text{C}_{3-6}\text{-heterocycloalkylring}$ can optionally be substituted with the group -NH_2 ,

wherein when A and B represent hydrogen, X represents -NH- and R^2 represents $\text{C}_{1-6}\text{-alkyl}$,

then R^1 represents $\text{-NH-(CO)-CH(NH}_2\text{)-(CH}_2\text{)}_2\text{-COOH}$ or $\text{-NH-(CO)-CH(NH}_2\text{)-(CH}_2\text{)}_2\text{-COOC}_2\text{H}_5$,

wherein when R^1 represents -COO-iso-propyl ,

then X represents -NH- and R^2 represents $\text{C}_3\text{-alkinyl}$ and A or B independently of one another represent the group -NO_2 or -NH-(CO)-CF_3 , and

wherein when R^1 represents halogen, X represents -NH- , B represents hydrogen and R^2 represents $\text{C}_{1-6}\text{-alkyl}$ substituted with -NH_2 ,

then A represents $\text{-NH-(CO)-C}_6\text{-cycloalkyl-NH}_2$,

or a diastereomer, enantiomer as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts salt thereof.


7. (Currently Amended) ~~Compounds of general formula (I)~~ A compound according to claim 6, + in which

A or B in each case independently of one another represent hydrogen or the group -NH-C₂H₄-OH, -NH-CH₂-hydroxyphenyl, -NH-(CO)-pyrrolidinyl, -NH-(CO)-CH(NH₂)-CH₂-phenyl, -NH-(CO)-pentyl-NH₂, -NH-(CO)-hexyl-NH₂, -NH-(CO)-CH₂-NH₂, -NH-(CO)-CH(NH₂)-hydroxyphenyl, -NH-(CO)-CH₂-hydroxyphenyl, -NH-(CO)-CH₂-methylphenyl, -NH-(CO)-C₂H₄-dihydroxyphenyl, -NH-(CO)-CH(OH)-phenyl, -NH-(CO)-CH(NH₂)-CH₂(OH), -NH-(CO)-C(CH₃)₂NH₂, -NH-(CO)-NH(C₂H₅), -CH₂OH, -(CO)-NH-cyclopropyl, -(CO)-NH-CH(CH₃)₂, ~~whereby the~~ wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH₂,

X represents an oxygen atom or the group -NH-,

R¹ represents halogen or hydroxymethyl and

R² represents -C₂H₅ optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl
or represents -C₃H₇ or -C₄H₈ optionally substituted in one or more places, the same way or differently with the group -NH₂, -NH-(CO)-CH(NH₂)-C₂H₄-COOH, -NH-(CO)-phenyl, -NH-(CO)-CH₂-phenyl, -NH-(CO)-CH₂-CH(CH₃)-phenyl, -NH-(CO)-CH₂-O-phenyl, -NH-(CO)O-CH₂-phenyl, -NH-(CO)-CH(NH₂)CH₂-phenyl,



whereby the wherein phenyl can optionally be substituted in one or more places, the same or differently, with halogen, -CH₃ or -(CO)-C(CH₂)(C₂H₅), or represents C₃-alkynyl,

or a diastereomer, enantiomer as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts salt thereof.

8. (Currently Amended) ~~Compounds of general formula (I)~~ A' compound according to claim 7, which is

N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

1-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

N-[3-[[5-bromo-4-[[3-[(5-oxo-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-dichloro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(4-bromo-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(2-p-tolyl-acetylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,
 Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-difluoro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
 Pyrrolidine-1-carboxylic acid {3-[5-bromo-4-(3-{2-[2,3-dichloro-4-(2-methylene-butyl)-phenoxy]-acetylamino}-propylamino)-pyrimidin-2-ylamino]-phenyl}-amide,
 Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[3-(2,3-dichloro-phenyl)-butyrylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
 Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(3-bromo-benzoylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,
N-(3-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[(2*R*)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[2*S*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,
N-[3-[[2*R*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,
 (α *R*)- α -Amino-*N*-[3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-(hydroxymethyl)phenyl]benzenepropanamide,
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-5-hydroxymethyl-phenylamino]-ethanol,
 (2*R*)-Amino-*N*-[3-hydroxymethyl-5-(4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
 3-((2*R*)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)- *N*-cyclopropyl-benzamide,
 3-((2*R*)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-*N*-isopropyl-benzamide,
 Phenylmethyl [3-[[2-[[3-[(ethylamino)carbonyl]amino]phenyl]amino]-5-(hydroxymethyl)pyrimidine-4-yl]amino]propyl]carbamate,

Pyrrolidine-1-carboxylic acid (3-{4-[3-((2R)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,
 Pyrrolidine-1-carboxylic acid (3-{4-[3-((2S)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-ethanol,
 1-Amino-cyclopentancarbonylic acid[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,
 1-Amino-cyclohexancarbonylic acid-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
 2-{[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-methyl}-phenol,
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(3,4-dihydroxy-phenyl)-propionamide,
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2S)-phenyl-acetamide,
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2R)-phenyl-acetamide,
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-hydroxy-propionamide,
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-phenyl]-3-hydroxy-propionamide,
 2-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-methyl-propionamide,
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide or
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide,
or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) ~~Compounds of general formula (I)~~ A compound according to claim 6, + in which

A or B in each case independently of one another represent halogen, hydrogen or the group -SO₂-CH₃, -NO₂, -NH₂, -CF₃, -CH₂-NH-(CO)-NH₂, -CH₂-pyrrolidinyl, -NH-(CO)-CH₃, -NH-(CO)-hexyl-NH₂, -NH-(CO)-phenyl, -NH-(CO)-pyrrolidinyl, --NH-(CO)-CH(NH₂)-CH₂-phenyl, NH-(CO)-OCH₃, -NH-(CO)-OCH(CH₃)₂, -NH-(CO)-OC₂H₄-morpholino, -NH-(CO)-NH-cyclopropyl, -NH-(CO)-morpholino, -NH-(CO)-NH-C₂H₄-morpholino, -NH-(CO)-NH-hydroxycycloalkyl, hydantoinyl,


~~whereby the~~ wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH₂ and

~~whereby the~~ wherein hydantoinyl can optionally be substituted with the group -CH₃ or -(CO)-thiazolidinonyl,

X represents the group -NH-,

R¹ represents halogen and

R² represents -CH₂-dihydroxyphenyl, -C₂H₄-imidazolyl, or -C₃H₇ optionally substituted in one or more places, the same way or differently, with



or a diastereomer, enantiomer as well as all related isotopes, diastereomers, enantiomers, solvates, polymorphs or pharmaceutically acceptable salts salt thereof.

10. (Currently Amended) ~~Compounds of general formula (I) according to claim 7~~ A compound, which is

4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-
urea,
1-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-3-
pyrrolidinol,
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
methyl ester,
N2-(3-aminophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-
cyclopropyl-urea,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-
morpholinecarboxamide,
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
1-methylethyl ester,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-
methanesulfonamide,
N2-(3-amino-5-(trifluoromethyl)phenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-
pyrimidinediamine,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(2-(4-
morpholinyl)ethyl)-urea,
N2-(3-amino-5-chlorophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
2-(4-morpholinyl)ethyl ester,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(4-

hydroxycyclohexyl)-urea,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-acetamide,
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-benzamide,
 (4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
 1-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 1-[3-[[2-[[3-[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
 (4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 3-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 (4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-

pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or
 (4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[[[(4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-
 imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A compound, which is ~~A compound of following structure~~
 N-(3-((4-((3-(aminomethyl)phenyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidine-
 carboxamide,
 4-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1-naphthaleneacetic
 acid,
 5-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1H-indole-2-
 carboxylic acid, ethyl ester,
 5-bromo-N4-[2-(1H-imidazol-5-yl)ethyl]-N2-(2-methyl-6-quinoliny)-2,4-pyrimidinediamine,
 4-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
 4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 5-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-1,3-dihydro-2H-
 benzimidazol-2-one,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl
 ester,
 3-amino-5-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid
 methyl ester,
 N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-
 methanesulfonamide,
 4-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl
 ester,
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-phenol,
 5-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-1H-isoindole-1,3(2H)-
 dione,

5-bromo-*N*⁴-(2-(1*H*-imidazol-4-yl)ethyl)-*N*²-(3-methylphenyl)-2,4-pyrimidinediamine,
N-(3-((5-bromo-4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-
 methanesulfonamide,
 4-((4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-5-methyl-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-
 benzenesulfonamide,
 4-((4-((3-aminopropyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((5-bromo-4-((3-(1*H*-imidazol-1-yl)propyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((5-bromo-4-((2-(1-pyrrolidinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid,
 4-((4-((3-((aminocarbonyl)amino)propyl)amino)-5-bromo-2-pyrimidinyl)amino)-
 benzenesulfonamide,
 4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid ethyl
 ester,
 4-((5-bromo-4-((4-(methylamino)butyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((5-bromo-4-((2-(1*H*-imidazol-1-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((5-ethyl-4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((4-((2-(1*H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((5-bromo-4-((2-(2-pyridinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 4-((5-bromo-4-((2-(1*H*-indol-3-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
 2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-acetamide,
N-(2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)ethyl)-acetamide,
 3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-propanamide,
N-(4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)butyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-
 furancarboxamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-1*H*-pyrrole-2-
 carboxamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanamide,
 N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-
 thiophenecarboxamide,
 4-((4-(4-(aminomethyl)-1-piperidiny)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,
~~4-(5-Brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-N,N-dimethylaminosulfonylamin,~~
~~1-Methyl-1H-imidazol-4-sulfonsäure [4-(5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-~~
~~phenyl]-amid,~~
4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-N,N-
dimethylaminosulfonylamin,
1-Methyl-1H-imidazol-4-sulfonic acid [4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-
phenyl]-amid,
 3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenol,
 4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester,
 3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
 2-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
 4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
 Methyl 3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-[(2-
 hydroxyethyl)amino]benzoate,
 Methyl 3-amino-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]benzoate or
 3-[Bis-(2-hydroxy-ethyl)-amino]-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic
 acid methyl ester,
or a pharmaceutically acceptable salt thereof.

12. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition comprising
~~as an active ingredient~~ at least one compound according to claim 1 ~~in an therapeutically effective~~

amount for the prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis together with an 6 and a pharmaceutically acceptable carrier, diluent or excipient.

13. (Cancelled)

17. (Currently Amended) ~~The use according to claim 13, wherein the disorder is selected from~~ A method of treating cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12 ~~angiofibroma, arthritis, eye diseases, auto-immune diseases, chemotherapy agent-induced alopecia and mucositis, Crohn disease, endometriosis, fibrotic diseases, hemangioma, cardiovascular diseases, infectious diseases, nephrological diseases, chronic und acute neurodegenerative diseases, like disruptions of nerval tissue, viral infections, to prevent restenosis of vessels, for preventing the formation of scars, preventing or treating keratoma seniles and contact dermatitis.~~

18. (Currently Amended) ~~The use~~ A method according to claim 17, wherein the cancer treated is a solid tumor, a tumor- ~~cancer stands for a solide tumours, tumour- or metastasis growth, Kaposi Sarkom, Hodgkin's disease or and/or leukemia, arthritis stands for rheumatoid arthritis, eyes diseases stand for diabetic retinopathy, neovaskular glaukoma, auto-immune diseases stand for psoriasis, alopecia and/or multiple sklerosis, fibrotic diseases stand for cirrhosis of the liver, mesangial cell proliferative diseases, arteriosklerosis, infectiouse diseases stand for diseases that are caused by unicellular parasites, eardiovascular diseases stand for stenosis, like stent induced restenosis, arteriosklerosis and restenosis, nephrological diseases stand for glomerulonephritis, diabetic nephropaty, malignant nephrosklerosis, thrombic mikroangiopathis syndrome, transplant rejections and glomerulopathy, chronic neurodegenerative diseases stand for Huntington's disease, amyotrophic lateralsklerosis, Parkinsons disease, AIDS, dementia und Alzheimer's disease,~~

~~acute neurodegenerative diseases stand for ischemias of the brain and neurotraumas, and viral infections stand for cytomegalic infections, herpes, hepatitis B or C and HIV.~~

19. (Currently Amended) A method according to claim 17, wherein the patient treated is of treating a mammal ~~having a disease state alleviated by the inhibition of Akt, Pdk, chk and/or VEGF-R activity, wherein the method comprises administering to a mammal a therapeutically effective amount of a compound according to claim 1.~~

20. (Currently Amended) ~~The~~ A method of claim 19, wherein the mammal is a human.

21-25. (Cancelled)


26. (New) A pharmaceutical composition comprising at least one compound according to claim 11 and a pharmaceutically acceptable carrier, diluent or excipient.

27. (New) A method of treating cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 26.

28. (New) A method according to claim 27, wherein the cancer treated is a solid tumor, a tumor- or metastasis growth, Kaposi Sarkom, Hodgkin's disease or leukemia.

29. (New) A method of treating rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

30. (New) A compound of formula (I)



in which

A or B

in each case independently of one another represent hydrogen or the group $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NR}^3\text{R}^4$, $-\text{N}(\text{C}_{1-6}\text{-hydroxyalkyl})_2$, $-\text{NH}(\text{CO})-\text{R}^5$, $-\text{NHCOOR}^6$, $-\text{NR}^7-(\text{CO})-\text{NR}^8\text{R}^9$, $-\text{NR}^7-(\text{CS})-\text{NR}^8\text{R}^9$, $-\text{COOR}^5$, $-\text{CO}-\text{NR}^8\text{R}^9$, $-\text{SO}_2-\text{CH}_3$, 4-bromo-1-methyl-1*H*-pyrazolo-3yl or C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group $-\text{NH}_2$, $-\text{NH}(\text{CO})-\text{R}^5$, $-\text{SO}_2-\text{NHR}^3$, $-\text{COOR}^5$, $-\text{CONR}^8\text{R}^9$, $-\text{O}(\text{CO})-\text{R}^5$, $-\text{O}(\text{CO})-\text{C}_{1-6}\text{-alkyl}-\text{R}^5$,

X


represents an oxygen atom or the group $-\text{NH}-$,

R^1

represents hydrogen, halogen, hydroxymethyl or the group $-\text{COOH}$, $-\text{COO}-\text{iso-propyl}$, $-\text{NO}_2$, $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{COOH}$ or $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{COO}-\text{C}_{1-6}\text{-alkyl}$,

R^2

represents C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group $-\text{NH}_2$, $-\text{NH}(\text{CO})\text{O}-\text{CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{H}$, $-\text{NH}(\text{CO})\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-O-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-CH}(\text{CH}_3)\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{-(CH}_2)_2\text{-COOH}$,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or -(CO)-C(CH₂)-C₂H₅, or represents C₃-alkinyl,

R³ or R⁴ in each case independently of one another represent hydrogen or C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, phenyl or hydroxyphenyl,

or

R³ and R⁴ together form a C₃₋₆-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more -(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C₃₋₆-heterocycloalkylring can optionally be substituted with C₁₋₆-alkyl, C₁₋₆-alkyl-COOH or C₁₋₆-alkyl-NH₂,

R⁵ represents C₁₋₆-alkyl, C₂₋₆-alkenyl, C₃₋₆-cycloalkyl or phenyl each can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy, phenyl or with the group -NH₂, -NH(CO)-O-C₁₋₆-alkyl, wherein phenyl can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy or C₁₋₆-alkyl,

R⁶ represents C₁₋₆-alkyl, C₂₋₆-alkenyl or phenyl,

R^7 represents hydrogen or C_{1-6} -alkyl and
 R^8 or R^9 in each case independently of one another represent hydrogen, C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{3-6} -cycloalkyl, aryl or phenyl, wherein aryl or phenyl can optionally be substituted in one or more places, the same way or differently, with hydroxy or the group $-NO_2$ or $-N(C_{1-6}\text{-alkyl})_2$
 or
 R^8 and R^9 together form a C_{3-6} -heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more $-(CO)-$ groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C_{3-6} -heterocycloalkylring can optionally be substituted with the group $-NH_2$,
 wherein when A and B represent hydrogen, X represents $-NH-$ and R^2 represents C_{1-6} -alkyl,
 then R^1 represents $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOH$ or $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOC_2H_5$,
 wherein when R^1 represents $-COO$ -iso-propyl,
 then X represents $-NH-$ and R^2 represents C_3 -alkinyl and A or B independently of one another represent the group $-NO_2$ or $-NH-(CO)-CF_3$, and
 wherein when R^1 represents halogen, X represents $-NH-$, B represents hydrogen and R^2 represents C_{1-6} -alkyl substituted with $-NH_2$,
 then A represents $-NH-(CO)-C_6\text{-cycloalkyl}-NH_2$,

or an isotope, solvate, polymorph or prodrug thereof.

31. (New) A compound according to claim 30, or a prodrug thereof, wherein said prodrug differs from said compound in that it has a free hydroxyl, free amino or free mercapto group bonded to an acetate, formate or benzoate group of said compound.

32. (New) A compound according to claim 6, wherein X represents an oxygen atom.

33. (New) A compound according to claim 6, wherein X represents the group -NH-.